Q-omics provides the consensus-scored XKR6 profile across patient tissues and cancer cell-line models. XKR6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, XKR6 is differentially expressed in 8, with the highest sampling consensus in BRCA. Additionally, XKR6 RNA expression shows 18,033 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight UCEC, BRCA, and UVM as cancer lineages where XKR6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for XKR6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes XKR6 survival associations across molecular data types. XKR6 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible XKR6 RNA expression–survival associations across cancer types. High XKR6 expression shows unfavorable associations in UCEC, MESO, OV and KIRP, but favorable associations in BLCA and LUAD. The UCEC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for XKR6 RNA expression.
This table summarizes XKR6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for XKR6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. XKR6 shows lower tumor expression in BRCA, LUAD, KICH and KIRC and higher tumor expression in COAD and CHOL. The BRCA box plot shows higher XKR6 RNA expression in normal versus tumor tissue (log2 FC = −0.337, t-test p < 0.001).
This table shows molecular features associated with XKR6 in patient tissues and cancer cell lines. In patient samples, XKR6 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, XKR6 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LIVER and LARGE_INTESTINE.
